Enlitic’s Growth Hinges on Funding Approval Amid Major GE HealthCare Partnership

Strategic Partnership with GE HealthCare

Enlitic, Inc. (ASX:ENL), a healthcare technology company specialising in AI-driven medical imaging software, has announced a significant milestone with the signing of a binding Memorandum of Understanding (MoU) with GE Precision Healthcare, LLC. This agreement sets the stage for Enlitic’s wholly owned subsidiary, Laitek Inc., to provide annual migration capacity services valued between US$3 million and US$6 million per year over the next five years. This translates to a potential revenue opportunity of up to A$50 million, contingent on Enlitic securing external funding.

Under the terms of the MoU, GE HealthCare will prepay US$2 million for Laitek’s migration services once Enlitic confirms it has raised a minimum of A$10 million from external sources. The MoU, while binding, is a framework for negotiating definitive agreements expected to be finalised by the end of 2025. This partnership also builds on Enlitic’s earlier designation as a foundational collaborator for GE HealthCare’s Genesis Cloud Product Suite, underscoring the strategic alignment between the two companies.

Capital Raise to Fuel Growth

To support this opportunity and accelerate its growth trajectory, Enlitic has launched a two-tranche equity raising to secure A$10 million. The placement involves issuing 250 million new Chess Depositary Interests (CDIs) at A$0.04 per CDI, representing discounts ranging from approximately 16% to 21% relative to recent trading prices. The first tranche, raising about A$5.8 million, will be completed under existing placement capacity, while the second tranche, targeting A$4.2 million, is subject to shareholder approval at the upcoming annual general meeting.

Participants in the placement will also be offered options exercisable at A$0.05 each, subject to shareholder approval. CEO Michael Sistenich has committed to subscribing for 1.25 million new CDIs, demonstrating management’s confidence in the company’s prospects. Taylor Collison is acting as lead manager for the placement.

Use of Funds and Outlook

The proceeds from the capital raise are earmarked for a balanced mix of research and development (A$2.7 million), sales and marketing (A$2.4 million), customer service, corporate expenses, and working capital. This allocation reflects Enlitic’s focus on enhancing its AI-enabled migration services and expanding its Ensight data intelligence suite, which aims to streamline healthcare providers’ transition to cloud infrastructure and improve clinical workflows.

Enlitic remains committed to achieving operational cashflow break-even by the end of calendar year 2025, a target that will be closely watched by investors given the company’s growth ambitions and the conditional nature of the MoU. The company has also highlighted key risks related to funding and market conditions in its investor presentation.

Strategic Implications

This MoU with a global healthcare giant like GE HealthCare not only validates Enlitic’s technology and business model but also positions it as a key player in the evolving landscape of AI-driven medical imaging and cloud migration services. The prepayment arrangement provides some upfront revenue certainty, while the five-year horizon offers a runway for scaling operations and deepening the partnership.

However, the ultimate revenue realisation depends on finalising definitive agreements and successfully executing the migration services. The equity raise, particularly the tranche subject to shareholder approval, introduces execution risk that market participants will monitor closely.